ALAR Pharmaceuticals Inc.

ALAR Pharmaceuticals, founded in 2016 in Taichung, Taiwan (TPEX: 6785), is a drug development company specializing in long-acting release products for CNS disorders and chronic diseases. Lead candidate ALA-1000 is a long-acting buprenorphine injectable for opioid use disorder. Pipeline also includes ALA-3000 (treatment-resistant depression), ALA-4000 (Parkinson's), and ALA-5000 (schizophrenia).